Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Technology Transfer”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1998

Keeping track of technology transfers.

Nurse managers can assess and control the influx of new technologies in their units and educate staff by understanding technology development history.

Diffusion of Innovation↗
PubMed1990

Vaccines in health strategies for developing countries--priorities and technology transfer.

Millions of people in developing countries are still at risk of dying of infectious diseases such as hepatitis B, typhoid, tuberculosis and cholera despite the existence of relevant vaccines. For economical reasons commercial firms are not keen to invest in new or improved vaccines meant for the Third World market. Yet some vaccines could be made cheaply if there was more effort in transfer of knowledge and technology between scientists of the technically developed countries and the Third World. National governments and research institutions should accept a special responsibility to mobilize available manpower and technical resources to provide the right vaccines at the right cost to those who need them the most. Without rapid progress in this field, developing countries will lack some of the most cost effective tools in their strategies for preventing disease, disability and death.

Developing Countries↗
PubMed2006

Technology transfer of Sabin-IPV to new developing country markets.

The Netherlands Vaccine Institute (NVI) developed the micro-carrier technology for large-scale production of IPV in the late 1960s and has used this technology successfully to produce IPV as well as DTP-IPV for the national immunization program in the Netherlands. As a public sector organization, and as one of the Millennium Development Goals, NVI has supported over the years access to vaccine technology like DTP and Hib for vaccine manufacturers in developing countries. In line with this role as a resource institute, NVI has recently been approached by a number of vaccine manufacturers, predominantly from developing countries, for transfer of IPV technology to meet the anticipated increase in demand for IPV following OPV cessation. Since WHO encourages new manufacturers to use the attenuated Sabin virus instead of wild polio strains in the production of IPV, NVI decided to respond positively to this WHO policy. The existing NVI experience in large-scale production of IPV and OPV using Vero cell based micro-carrier technology and its experience with experimental Sabin-IPV is an attractive start for the development of Sabin-IPV. This paper discusses the approach followed and the experience already gained in the project, as well as factors critical to its success.

Animals↗